+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Efficacy and Safety of Flosequinan, Given over 3 Days, Evaluated by Continuous Hemodynamic Monitoring

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The hemodynamic effects of flosequinan, a new balanced vasodilator, were evaluated in 12 patients with chronic congestive heart failure. The drug was added to diuretics and digitalis and given as an oral dose of 100 mg, once daily in the morning, over 3 days, and hemodynamic monitoring was performed before the first dose and for 72 h thereafter. Hemodynamic improvement, peaking between 1 and 2 h after oral administration, was observed on all 3 days. On day 1 pulmonary capillary wedge pressure (PCWP) was reduced from 27.8 ± 8.6 to 13.0 ± 3.1 mm Hg and cardiac output (CO) increased from 3.3 ± 0.6 to 4.5 ± 0.9 liters/min (p < 0.05). After 12–16 h the effect was slightly attenuated but remained significant at 24 h. A similar response was observed after the doses given on days 2 and3. At 72 h PCWP was 15.5 ± 4.1 mm Hg and CO 3.8 ± 1.1 liters/min (p < 0.05 for the difference from baseline). Heart rate was slightly increased only at 2 h after the dose. Pulmonary arterial and right atrial pressure and systemic and pulmonary vascular resistances were significantly reduced (except for systemic resistance at 72 h). In conclusion, flosequinan produces hemodynamic improvement in patients with chronic congestive heart failure. The response to subsequent doses is similar to the response to the first dose.

          Related collections

          Author and article information

          S. Karger AG
          11 November 2008
          : 76
          : 3
          : 201-205
          aGeriatric Cardiology Research Foundation and bRebecca Sieff Hospital, Safed, Israel; cDepartment of Clinical Research, Boots, Nottingham, UK
          174491 Cardiology 1989;76:201–205
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper


          Comment on this article